Retatrutide

Retatrutide is a synthetic peptide classified as a triple hormone receptor agonist, meaning it stimulates three different receptors involved in metabolism: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor ^[1]. It is being developed by Eli Lilly and is given as a once-weekly injection under the skin ^[1][2]. It belongs to the newer generation of incretin-based metabolic drugs that followed the GLP-1 agonists and the dual GIP and GLP-1 agonist class ^[3].

The compound is being investigated chiefly for obesity, but also for type 2 diabetes and metabolic dysfunction-associated fatty liver disease ^[2][3]. In a Phase 2, placebo-controlled trial in adults with obesity, retatrutide produced large, dose-related reductions in body weight over 48 weeks, with the highest-dose group losing roughly a quarter of body weight on average ^[2]. A related Phase 2 substudy in people with fatty liver disease reported marked reductions in liver fat ^[3]. A systematic review and meta-analysis of the early trials concluded that retatrutide was significantly more effective than placebo for weight loss, with a safety profile broadly comparable to control ^[4].

The rationale for combining three receptor targets is that each contributes differently: GLP-1 and GIP signaling curb appetite and improve blood-sugar control, while glucagon-receptor activation is thought to raise energy expenditure ^[1]. In the Phase 2 results, gastrointestinal symptoms were the most common side effects ^[2]. Retatrutide remains an investigational drug that has not been approved by regulators, with larger Phase 3 trials underway ^[4].

In trials the predominant effects are dose-dependent gastrointestinal ones, nausea, vomiting, diarrhea, and constipation, along with a modest rise in heart rate. It is still in Phase 3 testing and is not yet approved, so its long-term safety profile is not established.

Retatrutide is an investigational GIP/GLP-1/glucagon receptor triagonist without an approved label, so its interaction profile is inferred from established incretin-class pharmacology rather than dedicated retatrutide studies. As with other GLP-1 receptor agonists, it slows gastric emptying, which can alter the rate and extent of absorption of concomitant oral medications, a class effect noted for agents such as semaglutide. When added to insulin or insulin secretagogues (sulfonylureas), the class carries an increased risk of hypoglycemia that typically warrants dose reduction of the background agent. These concerns are theoretical for retatrutide specifically and drawn from the broader incretin class pending trial and labeling data. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Retatrutide, development code LY3437943, was created by Eli Lilly as a single peptide engineered to activate three metabolic hormone receptors at once: the GIP, GLP-1, and glucagon receptors. It advanced through early clinical development as an investigational once-weekly injectable for obesity, type 2 diabetes, and fatty liver disease. Its landmark phase 2 obesity trial, led by Ania Jastreboff and colleagues and published in the New England Journal of Medicine in 2023, reported substantial dose-dependent weight loss over 48 weeks ^[1]. On the strength of those results, retatrutide progressed into a large phase 3 program to confirm its efficacy and safety.

Retatrutide is among the most closely watched of the next-generation obesity drugs, generating considerable excitement because it adds a glucagon-receptor arm to the now-familiar GIP and GLP-1 actions, a combination thought to increase energy expenditure and reduce liver fat on top of appetite suppression. Its phase 2 weight-loss figures are frequently described as among the largest yet reported for an anti-obesity medication, fueling optimism about its potential. Observers also note its once-weekly dosing and effects on fatty liver disease as attractive features. In fairness, retatrutide remains investigational and is not approved; like other incretin-based agents it commonly causes dose-related gastrointestinal side effects, and trials noted a dose-dependent rise in heart rate.